http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20000036015-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42c7b52154d4e6a8650398bf1d1131f7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-107 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 |
| filingDate | 1997-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05f015bc162acff5f678e8c8b16f550a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3e6a8cf6f57e32401a7a673e98822f5 |
| publicationDate | 2000-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20000036015-A |
| titleOfInvention | Peptide prodrugs containing an alpha-hydroxyacid linker |
| abstract | Formula In n n Formula In n n X-L-Zn n n Peptide prodrugs. Wherein X refers to a pharmaceutically active peptide sequence, for example Leu-enkephalin,n n n Z is a peptide presequence of 2 to 20 amino acid units, preferably consisting of lysine and glutamic acid,n n n L is a linking group containing 3 to 9 backbone atoms, and the bond between C-terminal carbonyl and L of X is different from C-N amide bond.n n n Preferably, the bond between X and L is an ester bond. It has been found that it is possible to obtain a significant increase in resistance by proteolytic enzymes such as carboxypeptidase A, pepsin A, leucineaminopeptidase, α-chymotrypsin when blocking peptides of pharmacological activity as prodrugs of formula (I). It became. Prodrugs of Formula I are cleaved by plasma enzyme butyryl cholinesterase, which is readily reversible. Stability against enzymatic cleavage is believed to be due to the induced helix like structure. |
| priorityDate | 1996-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1224.